Thoratec Corp (NASDAQ:THOR)
| 31.49 Data as of May 20 |  -1.11 / -3.40%Today’s Change | 29.39 Today|||52-Week Range 39.86 | -16.07% Year-to-Date |
Latest THOR News | Press Releases
| FDA Nod for Thoratec Controller - Analyst Blog May 20 / Zacks.com | 1 Reason Thoratec May Be Headed for a Slowdown May 13 / MotleyFool.com |
| Thoratec Is Now Oversold (THOR) May 20 / TheStreet.com |
Today’s Trading
| Previous close | 32.60 |
| Today’s open | 32.13 |
| Day’s range | -- - -- |
| Volume | 1,438,390 |
| Average volume (3 months) | 649,456 |
| Market cap | $1.9B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/20/2013
Growth & Valuation
| Earnings growth (last year) | -21.01% |
| Earnings growth (this year) | -3.04% |
| Earnings growth (next 5 years) | +9.30% |
| Revenue growth (last year) | +16.31% |
| P/E ratio | 37.9 |
| Price/Sales | 4.42 |
| Price/Book | 3.15 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HTWRHeartWare Internatio... | -1.74 | -1.75% |
| CYBXCyberonics Inc | -0.15 | -0.30% |
| PCRXPacira Pharmaceutica... | -1.00 | -3.40% |
| CMNCantel Medical Corp | -0.32 | -0.92% |
Data as of 4:02pm ET, 05/20/2013
Financials
| Next reporting date | July 30, 2013 |
| EPS forecast (this quarter) | $0.43 |
| Annual revenue (last year) | $491.7M |
| Annual profit (last year) | $56.2M |
| Net profit margin | 11.42% |
Profile
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Gerhard F. Burbach, MBA |
CFO, VP & Senior Director-Investor Relations Taylor C. Harris |
Corporate headquarters Pleasanton, California |
Forecasts
